University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Thomas G. Martin III

Thomas G. Martin III, M.D.

Blood disorder specialist

A leading expert in hematology-oncology, Dr. Thomas Martin is the associate director of the Myeloma Program and director of the Unrelated Donor Transplantation Programs for adults at UCSF Medical Center. He is also clinical research director of hematologic malignancies, or blood cancers, at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants and is involved in efforts to improve the outcomes following unrelated donor transplants.

Martin earned an undergraduate degree at Cornell University and a medical degree at the University of Connecticut School of Medicine in Farmington, Conn. After a medical residency at Harbor-UCLA Medical Center in Torrance, Calif., He completed fellowships in hematology-oncology at UCSF, where he was promoted to an adjunct professor of medicine, division of hematology and oncology. In 1999, he joined MD Anderson Cancer Center as an assistant professor of medicine. In 2001, he rejoined the faculty at UCSF, where he is a clinical professor of medicine.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Conditions & Treatments

More about Thomas G. Martin III

Additional Languages

Spanish

Education

University of Connecticut, School of Medicine 1989

Residencies

Harbor-UCLA Medical Center, Internal Medicine 1992

Fellowships

UCSF Hematology/Oncology Division, Hematology/Oncology 1996

Selected Research and Publications

  1. Niesvizky R, Martin TG, Bensinger W, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee SJ, Orlowski RZ, Wang M. Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. Clin Cancer Res. 2013 Feb 27.
  2. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
  3. Martin TG, Clarke DR, Bowrey DJ. Medical students in theatre: setting the scene. Med Teach. 2012; 34(4):337.
  4. Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, Wolf J, Negrin R. Autologous hematopoietic cell transplantation for high-risk ALL. Bone Marrow Transplant. 2011 Mar; 46(3):460-1.
  5. Martin T, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M, O'Malley R, Hwang J, Linker C. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2010 Feb; 12(1):45-50.
  6. Damon L, Damon LE, Gaensler K, Kaplan L, Martin T, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008 Nov; 42(10):649-57.
  7. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64.
  8. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep; 38(6):421-6.
  9. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24.
  10. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Aug 1; 104(3):649-54.
  11. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia. 2003 Dec; 17(12):2538-40.
  12. Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, Linker C. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2003 Oct; 9(10):643-8.
  13. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003 Oct 15; 102(8):3052-9.
  14. Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002 Sep; 58(3):560-8.
  15. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9.
  16. Martin TG, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):97-120.
  17. Martin TG, Linker CA. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):121-43.
  18. Muench MO, Rae J, Bárcena A, Leemhuis T, Farrell J, Humeau L, Maxwell-Wiggins JR, Capper J, Mychaliska GB, Albanese CT, Martin T, Tsukamoto A, Curnutte JT, Harrison MR. Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease. Bone Marrow Transplant. 2001 Feb; 27(4):355-64.
  19. Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2001; 7(10):568-75.
  20. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, Körbling M. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol. 2000 Jun; 109(4):770-2.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California